A Study to Evaluate the Impact of Maintaining Hemoglobin Levels in Anemic Patients With Carcinoma of the Cervix

A Phase III Study to Evaluate the Impact of Maintaining Haemoglobin Levels Above 120g/L Verses Above 100g/L in Anaemic Patients With Carcinoma of the Cervix Receiving Concurrent Cisplatin and Radiation Therapy

Status

Suspended

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00921635

Acronym

HOSTT

Enrollment

Registered

2009-06-16

Start date

2008-04-30

Completion date

Unknown

Last updated

2009-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Cervical Cancer

Keywords

Haemoglobin

Brief summary

The purpose of this study is to assess the feasibility, safety and short term effects on health related quality of life, of maintaining hemoglobin from 120 to 130 g/L versus from 100 to 110 g/L, with red cell concentrate (RCC) transfusion, in women having chemo-radiation for cancer of the cervix.

Interventions

PROCEDUREBlood transfusion

Blood transfusion to maintain hemoglobin level above 120 g/L

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Previously untreated cervix cancer * FIGO stage IB2, II, IIIB, IVA * Suitable for treatment with radical intent using concurrent cisplatin and pelvic radiation

Exclusion criteria

* Hemoglobin level above 125g/L * Lower one-third vaginal involvement * Para-aortic lymphadenopathy

Design outcomes

Primary

Measure	Time frame
The impact of maintaining hemoglobin levels above 120 g/L versus above 100 g/L	5 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026